Results from two separate studies in the Journal of the American College of Surgeons showed a decision aid tool may help mitigate the sense of urgency patients feel about making treatment decisions.
Researchers have determined that offering brachytherapy for cervical cancer ends up costing hospitals money. That can leave hospitals -- and their patients -- in the lurch.
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.
For the first time the functions of natural killer cells in the womb have been identified.
The Dubin Breast Center of The Tisch Cancer Institute at the Mount Sinai Health System held its sixth annual benefit on Monday, December 11, 2017, at the Ziegfeld Ballroom in Manhattan.
A new study has found that women who had received chemotherapy and/or radiation to treat breast cancer were more likely to have high levels of DNA damage and reduced activity of an enzyme involved in chromosome healing, compared to women who underwent surgery alone. The results suggest that some breast cancer survivors may be more vulnerable to biological changes associated with accelerated aging because of their prior treatment.
Gene editing has captivated scientists and medical providers with tantalizing visions of wiping out debilitating inherited diseases.
Dr. Nathan Bryan, Baylor College of Medicine and one of the leading experts in nitric oxide biochemistry and physiology said today, “healthcare providers, especially those helping patients with cardiovascular issues and age-related disease, are not using perhaps the most important ‘tool’ in their ‘toolbox,’ restoring nitric oxide function. Bryan organized and chaired a full day workshop on the Clinical Applications of Nitric Oxide held during the 25th American Academy of Anti-Aging Medicine World Congress.
Citing uncertainties about the risks and benefits of an experimental therapy for fetuses whose kidneys do not develop, bioethicists at Johns Hopkins and a team of medical experts are calling for rigorous clinical trials in the use of a potential treatment, known as amnioinfusion.
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists.
Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, MD, executive director of the Basser Center for BRCA at Penn’s Abramson Cancer Center, will present new results from the Mediola and OlympiAD trials showing continued success of treating BRCA-related metastatic breast cancer with the PARP inhibitor olaparib with limited side effects for patients.
Intensive surveillance including a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) exam every six months was far more effective in detecting breast cancer in younger women with a high-risk genetic profile than an annual mammogram. DCE-MRI every six months performed well for early detection of invasive breast cancer in high-risk women.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Although digital breast tomosynthesis (DBT), or 3-D mammography, costs more than a digital mammography (DM) screening, it actually may help rein in cancer screening costs, according to preliminary findings (PD7-05) presented by researchers from the Perelman School of Medicine at the University of Pennsylvania during the 2017 San Antonio Breast Cancer Symposium.
La mamografía digital con realce por contraste es comparable a la resonancia magnética de las mamas para evaluar el cáncer mamario residual después de la terapia endocrina adyuvante o de la quimioterapia, según los resultados de un estudio presentado por los investigadores de Mayo Clinic.
The biological features of patients’ tumors partially explained a racial disparity for women with hormone receptor-positive, HER2-negative breast cancer, but UNC Lineberger researchers led by Katherine Reeder-Hayes, MD, MBA, MSc, said it didn’t explain it completely. The preliminary findings were reported at the 2017 San Antonio Breast Cancer Symposium.
Acupuncture decreased joint symptoms in women with early-stage breast cancer treated with aromatase inhibitors, according to a randomized, multicenter clinical trial led by researchers at NewYork-Presbyterian and Columbia University Irving Medical Center. The findings were presented at the San Antonio Breast Cancer Symposium, held Dec. 5 – 9.
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (PFS) in pre-menopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium.
Latest Research Highlights from ACSM
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right